Abbott Receives FDA Approval For Lower-Dose Of Antiretroviral Kaletra For Children
Main Category: HIV / AIDSAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 14 Nov 2007 - 10:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
5 (1 votes) |
Abbott Laboratories on Monday announced that it has received FDA approval to market and sell a lower-dose version of its antiretroviral drug Kaletra for children, the Chicago Sun-Times reports (Knowles, Chicago Sun-Times, 11/13). The tablet will be available in the U.S. this month, Bloomberg/Chicago Tribune reports. Kaletra has been available in liquid form for children since 2000, but the company in August warned health care providers to be cautious in prescribing Kaletra to children after the death of an infant who received an accidental overdose of the drug, Bloomberg/Chicago Tribune reports.
The new, lower-dose tablets can be taken with or without food and do not require refrigeration, which is an important advantage in treating children in developing countries, Abbott said. The new tablet will cost $2,100 annually per patient in the U.S. and $250 per patient annually in developing countries, the company said. The company added that approval in the European Union is pending, and once approved, it intends to make the drug available in more than 150 countries.
"We are expecting" the first step toward approval in the E.U. soon, Julie Herlocker, a spokesperson for Abbott, said, adding the company has an agreement with European regulators to ship the drug if it is requested directly by medical personnel (Bloomberg/Chicago Tribune, 11/13).
"HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world," Scott Brun, divisional vice president for infectious disease development at Abbott, said, adding, "Abbott developed a lower-strength tablet formulation of Kaletra to give physicians an innovative treatment option to help curb the impact of HIV infection in children" (Abbott release, 11/12).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/88692.php>
APA
http://www.medicalnewstoday.com/releases/88692.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




